MAP Enters Phase III For Pediatric Asthma Candidate, Targets AstraZenica’s Pulmicort
This article was originally published in The Pink Sheet Daily
Executive Summary
California firm says its unit-dose formulation of budesonide offers smaller dose, quicker nebulization through micro-particle technology.
You may also be interested in...
AstraZeneca Will Acquire Verus Asthma Program In Deal Worth $310 Million
Agreement will allow AstraZeneca to continue building its pediatric respiratory franchise, firm tells "The Pink Sheet" DAILY.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.